EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOTSG00005039075
Gene Symbol: LOC112227256
3 Cross references
180 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOTSG00005039614
Gene Symbol: LOC112227256
3 Cross references
180 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOTSG00005037279
Gene Symbol: LOC112227256
3 Cross references
180 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOTSG00005029827
Gene Symbol: CCR9
3 Cross references
185 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOTSG00005029972
Gene Symbol: CCR9
3 Cross references
185 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOTSG00005008128
Gene Symbol: CCR9
3 Cross references
185 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSOTSG00005032596
Gene Symbol: LOC112246046
2 Cross references
268 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSOTSG00005019132
Gene Symbol: LOC112225298
2 Cross references
268 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSOTSG00005029223
Gene Symbol: LOC112246046
2 Cross references
268 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOTSG00005036430
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOTSG00005018836
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOTSG00005029858
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).